GlassScriptPhysician profile
Nilam D Patel
NPI 1548538739
$9,800.42
in general payments reported to CMS, 2019-2025
42 companies · $3,423 in 2025
The $3,423 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $152 · 2022: $704 · 2023: $2,501 · 2024: $3,021 · 2025: $3,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,846 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,845.80 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,285.21 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $1,243.08 | 2022-2025 | |
| Novo Nordisk INC | $1,065.23 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $868.91 | 2022-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $774.31 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $546.00 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $512.71 | 2023-2025 | |
| Astellas Pharma US INC | $381.21 | 2023-2025 | Veozah |
| Amgen INC. | $326.31 | 2023-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $319.16 | 2022-2025 | Jardiance |
| Abbott Laboratories | $305.17 | 2022-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Freestyle Libre 3, Freestyle Libre 2 |
| Kowa Pharmaceuticals America, INC. | $271.48 | 2023-2025 | Zoryve, Seglentis, Livalo |
| Bayer Healthcare Pharmaceuticals INC. | $221.26 | 2023-2025 | |
| Exact Sciences Corporation | $184.08 | 2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $179.13 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $118.36 | 2023-2025 | Gattex, Trintellix |
| Otsuka America Pharmaceutical, INC. | $118.06 | 2024-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $100.15 | 2023-2025 | Voquezna |
| Optinose US, INC. | $96.78 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $78.44 | 2022-2025 | |
| Dexcom, INC. | $75.87 | 2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $71.94 | 2022-2025 | Belsomra, Capvaxive |
| Idorsia Pharmaceuticals US INC | $71.45 | 2022-2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $57.29 | 2022 | |
| Janssen Pharmaceuticals, INC | $52.86 | 2023-2024 | Xarelto |
| Almatica Pharma LLC | $51.03 | 2024-2025 | Loreev Xr |
| Lundbeck LLC | $48.42 | 2025 | Rexulti |
| Eisai INC. | $43.52 | 2024-2025 | |
| Amarin Pharma, INC. | $39.71 | 2022-2023 | |
| Inspire Medical Systems, INC. | $37.70 | 2024-2025 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.35 | 2024-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $29.28 | 2024-2025 | |
| Seqirus USA INC | $27.07 | 2024 | Flucelvax, Fluad |
| Ascensia Diabetes Care US INC. | $25.19 | 2024 | |
| Beta Bionics, INC. | $20.22 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Sanofi Pasteur INC. | $20.07 | 2024 | |
| Corcept Therapeutics | $19.40 | 2025 | Korlym |
| Ucb, INC. | $18.97 | 2023 | Briviact |
| Phadia US INC. | $18.52 | 2023 | Immunocap |
| Biogen, INC. | $17.16 | 2024 | Leqembi |
| Xeris Pharmaceuticals, INC. | $14.64 | 2024 | Gvoke Hypopen |
| Shield Therapeutics INC | $13.72 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nilam Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.